Erschienen in:
08.11.2018 | Preface
Human Ductal Carcinoma In Situ: from the Eyes of a Beholder
verfasst von:
Jason I. Herschkowitz, Fariba Behbod
Erschienen in:
Journal of Mammary Gland Biology and Neoplasia
|
Ausgabe 4/2018
Einloggen, um Zugang zu erhalten
Excerpt
“Why study DCIS if we can cure 97% of patients?” Most scientists studying DCIS will encounter this question. To patients that have faced this diagnosis and experienced the harsh and disfiguring consequences of currently-offered therapies, the answer is obvious. DCIS overdiagnosis and overtreatment is well documented in numerous studies, and the public health costs of unnecessary treatment are immense [
1‐
3]. Most importantly, patient survival that stands at ~97% for non-invasive DCIS plummets to 80% or lower when later more advanced stages of breast disease are discovered. Studying DCIS and how to prevent its progression is not a choice, but a necessity. Fortunately, recent findings using advanced technologies point to significant variation at the molecular, epigenetic, cellular and microenvironmental levels that highlight exciting new avenues for investigation. …
